Breaking News Instant updates and real-time market news.

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Acquired by CELG

$45.60

-3.15 (-6.46%)

17:27
01/16/18
01/16
17:27
01/16/18
17:27

Celgene in discussions to acquire Juno Therapeutics, WSJ reports

Celgene (CELG) is in talks to acquire Juno Therapeutics (JUNO), the Wall Street Journal reports. The discussions could lead to a deal in the coming weeks, the report says, citing people familiar with the matter. Terms of a potential transaction could not be learned, the Journal noted. Reference Link

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Acquired by CELG

$45.60

-3.15 (-6.46%)

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

CELG Celgene
$104.82

-1.18 (-1.11%)

01/08/18
ADAM
01/08/18
NO CHANGE
Target $140
ADAM
Buy
Celgene acquisition has 'interesting' upside potential, says Canaccord
After Celgene announced a deal to acquire Impact Biosciences for up to $7B, including an upfront payment of $1.1B, Canaccord analyst John Newman said the latter's JAK2 asset for myelofibrosis, fedratinib, showed an "interesting" 55% response rate in patients resistant or intolerant to Jakafi, which provides an immediately approvable FDA indication. This "carefully structured transaction" provides Celgene with substantial upside, assuming FDA approval, said Newman, who keeps a Buy rating and $140 price target on Celgene shares.
01/08/18
PIPR
01/08/18
NO CHANGE
Target $100
PIPR
Neutral
Celgene guidance 'a bit light' on sales, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views Celgene's preliminary Q4 results as "solid' but says the company's initial 2018 outlook is "a bit light" on revenue. The better than expected earnings outlook looks to be driven by expense management and lower than modeled share count, Raymond tell investors in a research note. He keeps a Neutral rating on Celgene with a $100 price target.
01/09/18
JEFF
01/09/18
NO CHANGE
Target $125
JEFF
Buy
Celgene likely 'too cheap and oversold,' says Jefferies
Jefferies analyst Michael Yee says that at 12 times earnings estimates, shares of Celgene are "probably too cheap and oversold." After meeting with management, Yee believes the company will do more deals following yesterday's acquisition of Impact. Further, he sees a potential share rebound on more pipeline readouts in 2018-2019. The analyst keeps a Buy rating on Celgene with a $125 price target.
01/09/18
BMOC
01/09/18
NO CHANGE
Target $147
BMOC
Outperform
Celgene 2018 outlook deliberately conservative, says BMO Capital
BMO Capital analyst M. Ian Somaiya says Celgene's 2018 guidance is "deliberately conservative", reflecting the management's decision to reduce the risk to near-term estimates amid investor focus on the company pipeline. Somaiya notes that investor focus is shifting to business development and the potential for more deals in the near-term as well as the data from the company's 12 phase III trials this year. The analyst keeps his Outperform rating and $147 price target on Celgene.
JUNO Acquired by CELG
$45.60

-3.15 (-6.46%)

11/03/17
RAJA
11/03/17
NO CHANGE
Target $61
RAJA
Outperform
Juno Therapeutics price target raised to $61 from $45 at Raymond James
Raymond James analyst Reni Benjamin raised Juno Therapeutics' price target to $61 from $45 and reiterated his Outperform rating following the Q3 report and update on all ongoing clinical programs. The analyst believes JCAR017 could potentially be a differentiated CAR T product and compete effectively with Yescarta and Kymriah. Further, with key readouts from multiple programs anticipated at upcoming medical conferences, the steady progress of the portfolio of products, including the BCMA CAR-T franchise as well as 5 products targeting solid tumors with data expected in 2018, and a strong cash position, Benjamin continues to recommend shares.
12/12/17
WELS
12/12/17
DOWNGRADE
Target $54
WELS
Market Perform
Juno Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Juno Therapeutics (JUNO) to Market Perform and cut his price target for the shares to $54 from $66. While data for JCAR017 continue to support a potential best-in-class profile in aggressive lymphoma, the current valuation already reflects dominant market positioning over Gilead's (GILD) Yescarta, Birchenough tells investors in a research note. The analyst also sees "some risk" to waning efficacy at six months for JCAR017.
12/12/17
12/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Juno Therapeutics (JUNO) downgraded to Market Perform from Outperform at Wells Fargo, with analyst Jim Birchenough saying that while data for JCAR017 continue to support a potential best-in-class profile in aggressive lymphoma, the current valuation already reflects dominant market positioning over Gilead's (GILD) Yescarta. 2. General Dynamics (GD) downgraded to Underweight from Neutral at JPMorgan, with analyst Seth Seifman saying Gulfstream questions are unlikely to be resolved in the near term. Demand for G500/600 is ok for now, but uncertainty about ultimate production levels and the pace of the learning curve mean the transition will remain a near term overhang, the analyst said. Seifman also downgraded Raytheon (RTN) to Neutral from Underweight. 3. Adobe (ADBE), Barracuda (CUDA), GoDaddy (GDDY), Fortinet (FTNT) and Check Point (CHKP) downgraded to Neutral from Overweight and CoStar Group (CSGP), Imperva (IMPV) and Monotype Imaging (TYPE) downgraded to Underweight from Overweight at JPMorgan by analyst Sterling Auty in conjunction with his 2018 annual outlook for Software Technology. The analyst does not expect the "exceptional performance" in Software during 2017 to repeat in 2018. 4. Spark Therapeutics (ONCE) downgraded to Neutral from Buy at UBS, with analyst Carter Gould seeing a "challenging setup" for the shares after the Phase 1/2 SPK-8011 data in hemophilia A fell short of expectations. The analyst removed SPK-8011, or $29 per share, and early-stage pipeline value, or $12 per share, from his model. He finds it difficult to be more constructive on Spark shares in the near-term. 5. Electronic Arts (EA) downgraded to Buy from Conviction Buy at Goldman Sachs by analyst Christopher Merwin to reflect fewer near-term catalysts around in-game monetization of non-sports titles. To see The Fly's full Street Research coverage, click here.
01/05/18
NEED
01/05/18
INITIATION
Target $65
NEED
Buy
Juno Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Juno Therapeutics (JUNO) with a Buy rating and a price target of $65. Messer says that while Novartis (NVS) and Gilead (GILD) have reached the CAR-T technology market ahead of Juno, the latter is "developing safer and potentially better products", positioning itself with "best-in-class technology". The analyst believes that the selloff in the stock price since the December ASH conference creates an attractive near-term entry point for investors.

TODAY'S FREE FLY STORIES

08:15
06/19/18
06/19
08:15
06/19/18
08:15
General news
Housing Starts Permits to be reported at 08:30 »

May Housing Starts…

08:15
06/19/18
06/19
08:15
06/19/18
08:15
General news
Housing Starts to be reported at 08:30 »

May Housing Starts will…

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

08:13
06/19/18
06/19
08:13
06/19/18
08:13
Periodicals
Jailed Audi CEO pledges to cooperate with emissions-cheating probe, WSJ reports »

CEO of Volkswagen's…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBCT

People's United

$18.74

0.02 (0.11%)

, FBNK

First Connecticut

$26.05

0.15 (0.58%)

08:13
06/19/18
06/19
08:13
06/19/18
08:13
Conference/Events
People's United to host conference call »

Conference call to…

PBCT

People's United

$18.74

0.02 (0.11%)

FBNK

First Connecticut

$26.05

0.15 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

NTRA

Natera

$14.38

0.12 (0.84%)

08:09
06/19/18
06/19
08:09
06/19/18
08:09
Hot Stocks
Natera announces research collaboration with Institut Jules Bordet »

Natera announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

BKYI

BIO-key

$2.42

0.02 (0.83%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
BIO-key awarded U.S. patent for Utilization of Biometric Data »

BIO-key International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRON

Cronos Group

$6.77

-0.25 (-3.56%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
Cronos Group granted medicinal cannabis Manufacture License in Australia »

Cronos Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CVS

CVS Health

$67.73

-2.37 (-3.38%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
CVS Pharmacy: Prescription delivery now available nationwide »

CVS Pharmacy, the retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNA

Allena Pharmaceuticals

$13.48

-0.08 (-0.59%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
Allena Pharmaceuticals completes animal proof-of-concept study for ALLN-346 »

Allena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$17.78

0.1 (0.57%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Downgrade
Mattel rating change  »

Mattel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$14.68

2.655 (22.08%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Downgrade
Rent-A-Center rating change  »

Rent-A-Center downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXR

Citius Pharmaceuticals

$2.67

-0.03 (-1.11%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Hot Stocks
Citius Pharmaceuticals announces Mino-Lok is now a registered trademark »

Citius Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRIX

IRIDEX

$6.19

-0.91 (-12.82%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Hot Stocks
IRIDEX announces approval of CYCLO G6 Glaucoma Laser system in Korea »

IRIDEX announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, DIA

Diamonds Fund ETF

$249.72

-0.99 (-0.39%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Technical Analysis
Technical Take: Diamonds Fund ETF breaks uptrend support line in pre-market »

As trade war and other…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

DIA

Diamonds Fund ETF

$249.72

-0.99 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSLS

ReShape Lifesciences

$3.07

-0.05 (-1.60%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Hot Stocks
ReShape Lifesciences receives issue notification for ReShape Vest patent »

ReShape Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTNB

Matinas BioPharma

$0.55

-0.0816 (-12.92%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Syndicate
Matinas BioPharma raises $8M in a public offering »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISR

IsoRay

$0.45

0.0095 (2.16%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Hot Stocks
IsoRay enters one-year employment contract with Lori Woods as Interim CEO »

IsoRay announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSKN

Strata Skin Sciences

$2.11

0.09 (4.46%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Hot Stocks
Strata announces 510(k) submission for Multi-Micro Dose tip accessory »

STRATA Skin Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$202.60

1.06 (0.53%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Hot Stocks
Raytheon awarded $161M contract from U.S. Army »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LASR

nLight

$38.51

-0.05 (-0.13%)

08:04
06/19/18
06/19
08:04
06/19/18
08:04
Recommendations
nLight analyst commentary  »

nLight price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$21.70

-0.1 (-0.46%)

08:04
06/19/18
06/19
08:04
06/19/18
08:04
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBNK

First Connecticut

$26.05

0.15 (0.58%)

08:03
06/19/18
06/19
08:03
06/19/18
08:03
Hot Stocks
Breaking Hot Stocks news story on First Connecticut »

First Connecticut trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$97.80

2.93 (3.09%)

, ANSS

Ansys

$177.91

0.17 (0.10%)

08:03
06/19/18
06/19
08:03
06/19/18
08:03
Recommendations
PTC, Ansys, Rockwell Automation analyst commentary  »

PTC price target raised…

PTC

PTC

$97.80

2.93 (3.09%)

ANSS

Ansys

$177.91

0.17 (0.10%)

ROK

Rockwell Automation

$175.40

-2.19 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

NCR

NCR Corp.

$32.23

0.06 (0.19%)

08:03
06/19/18
06/19
08:03
06/19/18
08:03
Hot Stocks
NCR Corp. announces strategic alliance with TCS »

NCR Corp. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEA

Easterly Government Properties

$20.17

0.14 (0.70%)

08:03
06/19/18
06/19
08:03
06/19/18
08:03
Syndicate
Easterly Government Properties 18M share Spot Secondary priced at $19.25 »

The company increased the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.